体内 T 细胞工程时代。

The era of in vivo T cell engineering.

机构信息

Department of Internal Medicine I, University Hospital Würzburg, and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany.

Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

出版信息

Med. 2022 Feb 11;3(2):85-86. doi: 10.1016/j.medj.2022.01.012.

DOI:10.1016/j.medj.2022.01.012

PMID:35590210

Abstract

Cell therapy with genetically engineered T cells has revolutionized the treatment of malignant diseases, but its potential use beyond the realms of oncology has been underexplored. In a recent study, Rurik et al. built on the technologies underlying mRNA vaccines to transduce T cells in vivo, harnessing them to target cardiac fibrosis.

摘要

利用基因工程改造的 T 细胞进行细胞治疗已经彻底改变了恶性疾病的治疗方法，但它在肿瘤学以外领域的潜在用途尚未得到充分探索。在最近的一项研究中，Rurik 等人在 mRNA 疫苗所基于的技术基础上，构建了在体内转导 T 细胞的方法，利用它们来靶向心脏纤维化。